TKT and acute myeloid leukemia: Approximately, 25% of AML patients have acquired FLT3 internal tandem duplications (FLT3-ITDs), varying from 3 to ≥ 400 base pairs in the juxtamembrane domain, and 7% of AML patients harbor activating point mutations in the second kinase domain (FLT3-TK) [7-10].